SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (2944)11/4/2013 4:02:15 PM
From: Zohar_Power  Read Replies (1) of 4474
 
Biomaven, from the top of my head, I recall that 66% of the PACE patients had been treated with Tasigna (if I am wrong, please correct me).

How to tease out, then whether Tasigna "sensitized" Iclusig patients for thrombolytic events, natural thromboloytic events that occur with CML patients (and other risk factors, such as age, triglycerides, hypertension, etc.) and any de-novo effect of Iclusig?

Also, the clinical patients for the Tasigna trials were younger and healthier coming off of Gleevec or Sprycell.
Some Iclusig patients had been on prior TKI therapy for over a decade!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News